ITM-11 showed superior PFS and ORR compared with everolimus in patients with gastroenteropancreatic neuroendocrine tumors.
Paige Britt
Advertisement
Articles by Paige Britt
Data from POTOMAC support durvalumab plus BCG and induction and maintenance therapy as a new treatment option in BCG-naive, high-risk NMIBC.
Advertisement
Latest Updated Articles
Durvalumab Combo Prolongs DFS in High-Risk BCG-Naive NMIBCPublished: October 17th 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Novel Blood-Based Prostate Cancer Test for Elevated PSA Levels
2
FDA Approves Updated Cosibelimab Label in Cutaneous Squamous Cell Carcinoma
3
Zanidatamab Shows Meaningful Benefit in HER2+ Biliary Tract Cancer
4
A Decline in the US Oncology Workforce: What Will the Next Decade Bring?
5
